title: Immunologic cross-reaction between HIV type 1 p17 and Mycoplasma hyorhinis variable lipoprotein.
abstract: Monoclonal antibodies directed against the HIV-1 matrix protein p17 that react with a component present on the surface of HIV-1-infected cells have previously been described. In this study we show that one of these monoclonal antibodies binds to persistently HIV-1-infected cell lines that are coinfected with Mycoplasma hyorhinis, but not to cell lines that are uninfected with mycoplasma. Mycoplasma-infected cells secrete HIV-1 at a higher rate, have a slight increase in cell surface expression of gp120 and gp41, and are less sensitive to immunotoxins than uninfected cells. The anti-p17 antibody binds to a protein of M. hyorhinis grown in cell-free culture. The variable expression and size of the protein among strains is typical of the variable lipoprotein (Vlp) system of M. hyorhinis. Confirmation of the reactivity of the antibody with a Vlp was provided by demonstrating its specific binding to recombinant VlpF expressed in E. coli, and to a synthetic peptide representing the carboxy-terminal region of VlpF, but not to other recombinant Vlp products or peptides. This is a true cross-reaction because the antibody also binds to recombinant p17 expressed in E. coli and the binding is inhibited by the VlpF peptide. These analyses highlight the potential of mycoplasma contamination of tissue culture cell lines to cause anomalous results. With regard to HIV-1, mycoplasma infection of cells results in increased rates of virus secretion, and introduces a potential confounding immunologic cross-reaction as well. The existence of a cell surface form of p17 is unlikely.
authors.affiliation: Laboratory of Microbial Structure and Function, NIAID Rocky Mountain Laboratories, Hamilton, Montana 59840, USA.
authors.forename: S H
authors.initials: SH
authors.lastname: Pincus
authors.forename: R L
authors.initials: RL
authors.lastname: Cole
authors.forename: R
authors.initials: R
authors.lastname: Watson-McKown
authors.forename: A
authors.initials: A
authors.lastname: Pinter
authors.forename: W
authors.initials: W
authors.lastname: Honnen
authors.forename: B
authors.initials: B
authors.lastname: Cole
authors.forename: K S
authors.initials: KS
authors.lastname: Wise
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology*; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology*; D001426:Bacterial Proteins / Q000276:immunology*; D002478:Cells, Cultured; D003429:Cross Reactions / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D015683:Gene Products, gag / Q000276:immunology*; D015488:HIV Antigens / Q000276:immunology*; D015497:HIV-1 / Q000254:growth & development / Q000276:immunology* / Q000302:isolation & purification; D015151:Immunoblotting; D008074:Lipoproteins / Q000276:immunology*; D009174:Mycoplasma / Q000254:growth & development / Q000276:immunology* / Q000302:isolation & purification; D014764:Viral Proteins; D054301:gag Gene Products, Human Immunodeficiency Virus
chemical_list: D000911:Antibodies, Monoclonal; D001425:Bacterial Outer Membrane Proteins; D001426:Bacterial Proteins; D015683:Gene Products, gag; D015488:HIV Antigens; D008074:Lipoproteins; D014764:Viral Proteins; C095880:VlpF protein, Mycoplasma hyorhinis; D054301:gag Gene Products, Human Immunodeficiency Virus; C054858:p17 protein, Human Immunodeficiency Virus Type 1